FDA staff raises concern about risks tied to lung drug Spiriva

11/17/2009 | Reuters

FDA reviewers plan to ask an advisory panel to examine safety concerns such as the risk of stroke, heart attack or cardiovascular-related death linked to Pfizer and Boehringer Ingelheim's lung drug Spiriva. The product is scheduled for expanded-approval review as a treatment for flare-ups of chronic obstructive pulmonary disease.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ